Acadia is funding and executing the development however under the agreement with Acadia Neuren gets input through a joint steering committee. Acadia has clearly prioristised Retts.
I also believe, although could be wrong, Fragile X may come under a different division with the FDA (Neurology vs Psychiatry). This would require a different approach to any potential P3 trial. As i said though, i coudl be wrong on that.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.70 |
Change
0.220(1.33%) |
Mkt cap ! $2.104B | |||
| Open | High | Low | Value | Volume |
| $16.65 | $16.90 | $16.33 | $5.569M | 332.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1333 | $16.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.78 | 30 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |